Andere talen Caplin Point Laboratories Limited NSE India S.E.

Aandelen

CAPLIPOINT

INE475E01026

Beurs gesloten - NSE India S.E. Andere beurzen 13:40:29 16-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1.534 ^INR	+0,96%		-0,09%	+13,11%

11/06	Caplin Point Laboratories Limited benoemt Thiagaraja Manikandan tot Chief Transformation & Digital Officer	CI
24/05	Caplin Point Arm krijgt groen licht van de Amerikaanse FDA voor fenylefrinehydrochloride oogheelkundige oplossing	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Caplin Point Laboratories Limited Appoints Thiagaraja Manikandan as Chief Transformation & Digital Officer	11/06
Caplin Point Arm Gets US FDA's Nod for Phenylephrine Hydrochloride Ophthalmic Solution	24/05
Caplin Point Laboratories to Seek Acquisitions	16/05
Caplin Point Laboratories Limited Declares an Interim Dividend for the Financial Year Ended March 31, 2024	16/05
Caplin Point Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	16/05
Caplin Point Laboratories Gets Colombian Drug Regulator's Approval for Soft Gel Capsules Unit in India	06/05
Caplin Point Laboratories Limited Receives Colombia's INVIMA Approval for Its Softgel Capsules Division At Puducherry	06/05
Caplin Point Arm Gets US FDA Final Nod for Ofloxacin Ophthalmic Solution	16/04
Caplin Point Unit Receives US FDA Nod for Eye Treatment Medication	28/03
Caplin Steriles Limited, A Subsidiary of Caplin Point Laboratories Limited Gets USFDA Approval for Ketorolac Tromethamine Ophthalmic Solution	28/03
Caplin Point Laboratories Arm Starts Operations of Oncology Facility at Kakkalur, India	27/03
Caplin One Labs Limited, a Wholly Owned Subsidiary of Caplin Point Laboratories Limited Successfully Completes New Oncology (Anti-Cancer) Facility, Commences Operations	27/03
Caplin Point Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	09/02
Caplin Point Laboratories to Invest INR7 Billion in Tamil Nadu, India	08/01
Caplin Point Unit Gets US FDA Final Approval for Generic Ear Infection Drug	08/01
Caplin Point Laboratories Limited Announces Resignation of Hero Velladurai as President, R&D	14/12
Caplin Point Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11
Caplin Point Laboratories Limited Approves Final Dividend for the Year Ended March 31, 2023	22-09-23
Caplin Point Unit's Injectable and Ophthalmic Plant in India Gets VAI Classification from US FDA	04-09-23
Caplin Point Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	07-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Caplin Point Laboratories Limited NSE India S.E.

Aandelen

CAPLIPOINT

INE475E01026

Andere talen

Filters